Publications by authors named "A Maassenvandenbrink"
The association between migraine and cognitive function has been studied during the last decade, however, this relationship is not well established. As migraine prevalence is highest between the ages of 30-40, aligning with some of our most productive years, we must understand cognitive changes within this disorder. Cognitive impairment potentially limits social and professional interactions, thus negatively impacting quality of life.
View Article and Find Full Text PDFImportance: A previous cohort study in the US found that women with higher cardiovascular risk were more likely to have a history of migraine but less likely to have active migraine. Extrapolating these results to men and European individuals is crucial to understanding the complex association between migraine activity status and vascular health in other populations.
Objective: To evaluate the association pattern between a cardiovascular risk score, the most recent European version of the Systematic Coronary Risk Evaluation 2 (SCORE2) risk estimation system, and migraine activity status in Dutch men and women.
Background: Different responses in human coronary arteries (HCA) and human middle meningeal arteries (HMMA) were observed for some of the novel CGRP receptor antagonists, the gepants, for inhibiting CGRP-induced relaxation. These differences could be explained by the presence of different receptor populations in the two vascular beds. Here, we aim to elucidate which receptors are involved in the relaxation to calcitonin gene-related peptide (CGRP), adrenomedullin (AM) and adrenomedullin 2 (AM2) in HCA and HMMA.
View Article and Find Full Text PDFArticle Synopsis
- Orally administered second-generation gepants are effective for migraine treatment, while the new third-generation gepant, zavegepant, offers potential benefits like faster action through intranasal delivery.
- The study investigated zavegepant's ability to block the effects of calcitonin gene-related peptide (CGRP) in human arteries, revealing it to be a potent antagonist at certain concentrations.
- Findings suggest that zavegepant's lower potency at systemic levels highlights the importance of intranasal delivery, which could be particularly advantageous for specific patient populations, such as those who are overweight.